Clinuvel Pharmaceuticals Limited

ASX:CUV Stock Report

Market Cap: AU$689.2m

Clinuvel Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Clinuvel Pharmaceuticals has been growing earnings at an average annual rate of 14.4%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 23.9% per year. Clinuvel Pharmaceuticals's return on equity is 16.9%, and it has net margins of 36.9%.

Key information

14.4%

Earnings growth rate

13.8%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate23.9%
Return on equity16.9%
Net Margin36.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jun 27
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

May 09
Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Mar 24
Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18
An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20
Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30
Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27
Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14
Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03
This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23
A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23
Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10
With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06
Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27
Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20
What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01
Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14
Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28
We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21
What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Revenue & Expenses Breakdown
Beta

How Clinuvel Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:CUV Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 238230291
30 Sep 238030271
30 Jun 237831251
31 Mar 237429231
31 Dec 227026211
30 Sep 226824201
30 Jun 226621191
31 Mar 226222181
31 Dec 215724171
30 Sep 215324161
30 Jun 214825141
31 Mar 21432314-1
31 Dec 20382114-3
30 Sep 20351813-1
30 Jun 203315120
31 Mar 203215104
31 Dec 19321588
30 Sep 19321677
30 Jun 19311867
31 Mar 19291767
31 Dec 18271666
30 Sep 18261566
30 Jun 18251366
31 Mar 18211065
31 Dec 1717665
30 Sep 1717764
30 Jun 1717754
31 Mar 1714554
31 Dec 1612344
30 Sep 169044
30 Jun 167-354
31 Mar 165-533
31 Dec 154-623
30 Sep 154-843
30 Jun 153-1063
31 Mar 153-1083
31 Dec 143-1093
30 Sep 143-873
30 Jun 143-653
31 Mar 143-653
31 Dec 132-653
30 Sep 132-654
30 Jun 132-754
31 Mar 132-755

Quality Earnings: CUV has high quality earnings.

Growing Profit Margin: CUV's current net profit margins (36.9%) are lower than last year (37.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CUV's earnings have grown by 14.4% per year over the past 5 years.

Accelerating Growth: CUV's earnings growth over the past year (14.2%) is below its 5-year average (14.4% per year).

Earnings vs Industry: CUV earnings growth over the past year (14.2%) exceeded the Biotechs industry -9.3%.


Return on Equity

High ROE: CUV's Return on Equity (16.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.